Last reviewed · How we verify
Dalbavancin administration
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Acute bacterial skin and skin structure infections (ABSSSI), Gram-positive bacterial infections including MRSA.
At a glance
| Generic name | Dalbavancin administration |
|---|---|
| Also known as | Xydalba® administration |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Lipoglycopeptide antibiotic |
| Target | Bacterial peptidoglycan (D-Ala-D-Ala) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Dalbavancin works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, preventing proper cell wall formation and leading to bacterial cell death. It has a long half-life (approximately 14 days) allowing for extended dosing intervals. The drug is effective against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens.
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI)
- Gram-positive bacterial infections including MRSA
Common side effects
- Infusion-related reactions
- Nausea
- Headache
- Diarrhea
- Vomiting
Key clinical trials
- A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia (PHASE1)
- Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. (PHASE4)
- Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus (PHASE3)
- Efficacy and Safety of Dalbavancin As Suppressive Therapy
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia (PHASE2)
- Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA (PHASE3)
- Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |